Skip to main content
Millenn Chiwewe on Muck Rack

Millenn Chiwewe

As seen in: Nature
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Millenn

Contact Millenn, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Combined ctDNA and serum PSA for dynamic monitoring of metastatic prostate cancer starting first-line treatment: a prospective national cohort study

|
By Anuradha Jayaram, Alison Reid, Francesco Orlando, Leila Zakka, Miriam Gonçalves, Constantine Alifrangis, Rob Jones Verified, Sarah H. Needleman, Diletta Bianchini, Anna Wingate, Kenrick Ng, Mark Linch, Ursula McGovern, John Staffurth, Simon J Crabb, Alison Birtle, Osvaldas Vainauskas, Gianmarco Leone, Allan Hackshaw, Andre Romualdo Lopes, André D. Lopes, Daniel Wetterskog, Francesca Demichelis, Gerhardt Attard, Memuna Rashid, Suparna Thakali, Jacqueline O’Dwyer, Elias Pintus, Susannah Brock, Millenn Chiwewe
| Nature Verified
Abstract The prognosis of newly diagnosed metastatic prostate cancer is highly variable. The primary objective of the PARADIGM prospective cohort study was to evaluate predictors of survival in blood collected at the start of each of the first six treatment cycles from 114 patients with high-volume metastatic prostate cancer (biologically male) who were starting androgen deprivation therapy in combination with docetaxel or an androgen receptor pathway inhibitor.
Open in Who Shared Issue with article?
See all 1 articles